🫀 Vedolizumab in Pregnancy: New Meta-Analysis Highlights
🔥 Main in 3 points
- Vedolizumab not linked to higher risk of early pregnancy loss, congenital malformation, or composite perinatal complications in IBD patients.
- Increased odds of preterm birth (OR=1.33) and cesarean delivery (OR=1.27) seen, though likely reflecting underlying disease severity, not direct drug effect.
- Overall, safety profile supports vedolizumab use in pregnancy when needed.
🧪 Context
Systematic review and meta-analysis (8 cohort studies, n not specified); maternal, fetal, and neonatal outcomes; compared vedolizumab-exposed versus non-exposed pregnancies in IBD.
📍 Practical significance
Discuss preterm birth and C-section risk when counseling pregnant IBD patients. Vedolizumab remains a reasonable choice for women requiring ongoing biological therapy during pregnancy, given no increased risk of fetal loss or malformations was found.
🔗 PubMed | Journal Link
🧪 Individualized Vedolizumab Dosing in Pregnancy: Population PK Model Breakthrough
🌀 What was studied
Population PK model in 39 pregnant women with IBD on vedolizumab; albumin trends and gestational effects modelled to propose optimised dosing.
📈 Key results
- Pregnancy led to 52.4% ↑ in drug volume of distribution and 38.6% ↑ in clearance; additional 33.3% clearance boost in 3rd trimester.
- Vedolizumab trough levels declined nearly 50% by late pregnancy without dose adjustments.
- For ~1/3 of women, optimal exposure required dose interval shortening (e.g., to ~5.6 weeks if previously on Q8W).
📍 What this changes in practice
Consider albumin decline and pregnancy stage when planning vedolizumab dosing. Use nomogram-based guidance for interval adjustments. Enhanced PK understanding supports safer, more effective biologic therapy during pregnancy.
🔗 PubMed | DOI
✅ How does vedolizumab’s infection risk compare to other advanced therapies in IBD?
- Large nationwide cohort (>99,000 IBD patients, 2007-2023) assessed serious infection rates with biologics and small molecules—including vedolizumab—vs. the general population.
- Key findings: Serious infection risk is higher in all IBD patients (adjusted HR for naïve: 1.89), and further increased with immunomodulators (aHR 4.45) and advanced therapies (aHRs 3.45–10.55). Pediatric patients and those with GI/opportunistic infections were especially at risk.
- No significant difference in serious infection rates between vedolizumab, anti-TNF agents, ustekinumab, JAK inhibitors, or other advanced therapies after matching.
📍 How to apply: When starting or continuing vedolizumab (or other advanced therapies), infection vigilance is essential, but vedolizumab does not show a higher infection risk relative to other agents.
🔗 PubMed | Journal Link
|
